Immune checkpoint inhibitor usage and immune-related adverse event (irAE) incidence over time
| Event | Therapy class | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | Total | |
| Number of patients | 19 177 | % of total | ||||||||||
| Pembrolizumab | PD-1 | – | – | – | – | 113 | 393 | 1341 | 2342 | 3385 | 7574 | 39.5% |
| Nivolumab | PD-1 | – | – | – | – | 422 | 1702 | 1652 | 1922 | 1669 | 7367 | 38.4% |
| Ipilimumab | CTLA-4 | 71 | 193 | 196 | 319 | 306 | 205 | 140 | 74 | 57 | 1561 | 8.1% |
| Nivolumab combination therapy | – | – | – | – | 17 | 129 | 219 | 478 | 566 | 1409 | 7.3% | |
| Atezolizumab | PD-L1 | – | – | – | – | – | 57 | 207 | 278 | 658 | 1200 | 6.3% |
| Avelumab | PD-L1 | – | – | – | – | – | – | 6 | 31 | 26 | 63 | 0.3% |
| Pembrolizumab combination therapy | – | – | – | – | – | – | 2 | 1 | – | 3 | 0.0% | |
| Number of irAEs | 504 | |||||||||||
| Pembrolizumab | PD-1 | – | – | – | – | – | 13 | 36 | 67 | 50 | 166 | 32.9% |
| Nivolumab | PD-1 | – | – | – | – | 10 | 58 | 52 | 54 | 32 | 206 | 40.9% |
| Ipilimumab | CTLA-4 | – | 2 | 4 | 6 | 17 | 6 | 6 | 1 | – | 42 | 8.3% |
| Nivolumab combination therapy | – | – | – | – | – | 16 | 11 | 30 | 21 | 78 | ||
| Atezolizumab | PD-L1 | – | – | – | – | – | – | 4 | 5 | 2 | 11 | |
| Avelumab | PD-L1 | – | – | – | – | – | – | – | 1 | – | 1 | |
| irAE/patient year | 0.0% | 1.0% | 2.0% | 1.9% | 3.1% | 3.7% | 3.1% | 3.1% | 1.7% | 2.6% | ||
CTLA-4, cytotoxic T lymphocyte-associated 4; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.